Using Bioactive Glass to Treat Diabetic Foot Osteomyelitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a multicenter randomized trial aimed at evaluating the effectiveness and safety of S53P4 bioactive glass in the surgical management of osteomyelitis in the forefoot of diabetic patients. Participants will be randomly assigned to two groups: one receiving standard surgical treatment with or without bone substitutes, and the other receiving debridement with the addition of bioactive glass. The study will monitor patient outcomes post-surgery, focusing on healing and infection control. The trial is conducted in specialized centers to ensure high-quality care and adherence to protocols.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent obtained.
2. Male or female patients \>= of 18 years old.
3. They should have type I since at least 5 years or type II DM
4. They should have a diagnosis - confirmed by imaging and culture - of OM localized in the forefoot not responding for at least 2 up to 6 weeks to systemic antibiotic therapy and/or associated with soft tissue infection, abscess, phlegmon, necrosis, and for which a surgical debridement is indicated.
5. They should have palpable pulses on TP or DP at the ankle in the affected limb, and/or ABPI \>0.7 and \<1.2 and /or TcPO2 at dorsum of the foot ≥36 mmHg.
6. They should be able to accomplish with the procedures and prescriptions indicated by the Study protocol, particularly with the offloading prescription, as well as they should be willing and able to attend and respect the program of control visits and medications.
7. Anatomical area: forefoot.

Exclusion Criteria:

1. They should not have metabolic decompensation as witnessed by HbA1c \>109 mmol/mol (\> 12%).
2. They should not have major amputation on the contra-lateral limb.
3. They should not have acute or chronic Charcot's foot in the affected foot.
4. They should not have undergone surgical or endovascular revascularization in the affected foot in the month preceding the enrollment.
5. They should not be taking corticosteroids, bisphosphonates, immunosuppressants, and more in general any drug which might interfere with bone metabolism or tissue repair, in thejudgment of investigators.
6. They should not have ESRD in dialysis.
7. They should not be bedridden or not ambulating.
8. They should not have a life expectancy shorter than one year.
9. They should not be too ill to sustain a surgical procedure under loco-regional anesthesia.
10. They should not have severe disease which might interfere with the expected course of the disease and therapy.
11. Hypersensitivity to any product ingredient(s) or history of anaphylactic reactions.
12. Participation in another interventional studies within 45 days prior to the start of the present study.
13. Predictable poor compliance or inability to communicate well with the investigator.

Where it's running

• ASST Ovest Milanese - Ospedale di Abbiategrasso
  Abbiategrasso, Milano, Italy Recruiting
• ASUGI Azienda Sanitaria Universitaria Giuliano Isontina - Ospedale Monfalcone
  Monfalcone, Gorizia, Italy Not yet recruiting
• Casa di Cura Abano Terme - POLICLINICO ABANO TERME
  Abano Terme, Padova, Italy Not yet recruiting
• USL Sud Est Toscana - Ospedale San Donato
  Arezzo, Italy Not yet recruiting
• AUSL Romagna - Ospedale Morgagni Pierantoni
  Forlì, Italy Not yet recruiting
• Azienda USL Toscana Nord Ovest - Ospedale Campo di Marte
  Lucca, Italy Not yet recruiting

Study contacts

• Principal investigator: Dr. Roberto De Giglio, Med Doctor — ASST Ovest Milanese
• Study coordinator: Dr. Roberto De Giglio, Med Doctor
• Email: roberto.degiglio@asst-ovestmi.it
• Phone: +39 331 6989775

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing oral beta-lactam and non-beta-lactam antibiotics for leg and foot bone infections

  This trial will test whether oral beta-lactam antibiotics work as well as other oral antibiotics for adults with bone infections of the lower leg or foot.

  Recruiting Phase 4 Michael Garron Hospital · Ottawa, Ontario and 2 other locations · NCT07266753

• Registry for the CERAMENT G device in treating bone infections

  This study is collecting information on how well the CERAMENT G device works for treating bone infections in adults over three years.

  Recruiting at 3 sites Bonesupport Ab · San Diego, California and 2 other locations · NCT06010433

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.